Literature DB >> 27070847

Clinical Manifestations of Zika Virus Infection, Rio de Janeiro, Brazil, 2015.

José Cerbino-Neto, Emersom Cicilini Mesquita, Thiago Moreno L Souza, Viviane Parreira, Bernardo Bastos Wittlin, Betina Durovni, Maria Cristina Ferreira Lemos, Alexandre Vizzoni, Ana Maria Bispo de Filippis, Simone Alves Sampaio, Bianca de Santis Gonçalves, Fernando A Bozza.   

Abstract

Entities:  

Keywords:  Brazil; Flaviviridae; PHEIC; Rio de Janeiro; Zika fever; Zika virus; arthralgia; conjunctivitis; exanthema; fever; flavivirus; headache; joint swelling; myalgia; public health emergency of international concern; rash; surveillance; symptom; viruses

Mesh:

Year:  2016        PMID: 27070847      PMCID: PMC4918188          DOI: 10.3201/eid2207.160375

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the editor: Zika virus infection, which has been associated with microcephaly and other neurologic disorders, has reached the level of public health emergency of international concern (). Zika virus (family Flaviviridae, genus Flavivirus) is transmitted by mosquitos of the genus Aedes (). The virus was first isolated from a serum specimen from a rhesus monkey in the Zika Forest of Uganda in 1947 (). After 2007, a rapid geographic expansion of the virus was observed, including outbreaks in the Pacific region () and, more recently, in South America. Brazil reported the first autochthonous case of Zika virus disease in April 2015 (), and subsequently, increasing numbers of cases have been reported, especially in northeastern Brazil (). Studies on the natural history of Zika virus infection are scarce. Previous research defined Zika virus infection as a dengue-like illness, typically characterized by fever, maculopapular rash, arthralgia, and conjunctivitis (). Although some patients have all of these symptoms during early onset, fever is not an early symptom for all. Here we describe the frequency of signs and symptoms from a sample of clinic patients in Rio de Janeiro, Brazil, who were later confirmed to have Zika virus disease by using real-time reverse transcription PCR (rRT-PCR). We retrospectively collected clinical data on a convenience sample of 57 patients found to be Zika virus–positive by rRT-PCR who had medical attention at the 24-hour acute care clinic of Manguinhos in Rio de Janeiro during April 28–June 8, 2015. Data were collected from electronic medical records and surveillance reports. Data were anonymized and included age, sex, and signs and symptoms documented on the first clinic visit of patients who reported acute rash, dengue-like illness, or both. Fever was documented either through direct measurement in the clinic or by patient self-report. Pregnancy status was not assessed. We collected blood samples for serum sample testing during each patient’s initial visit to the clinic and tested for Zika virus using rRT-PCR as described by Lanciotti et al. (); all samples were collected within 7 days of illness onset. Patients were not tested for dengue or chikungunya viruses. We did not measure the duration of any sign or symptom. Of the 57 Zika virus disease case-patients, median age was 34 years; 63% were women (Table). The most common sign or symptom was exanthema (98%), followed by headache (67%), fever (67%), arthralgias (58%), myalgias (49%), and joint swelling (23%) (Table). Conjunctivitis was observed in 39% case-patients and retro-orbital eye pain was reported by 40%. Among 30 patients who had fever assessed by clinic staff, median temperature was 38°C (range 37.5°C –38.5°C). One patient had no rash or joint swelling but did have all other symptoms. One patient’s sole symptom was rash. No patients were referred for hospitalization.
Table

Characteristics of Zika virus disease patients seeking care in an acute care clinic, Rio de Janeiro, Brazil, April 28–June 8, 2015

CharacteristicValue*
Cohort, no. patients57
Age, y34 (25–40)
Female sex
36 (63)
Symptoms
Exanthema56 (98)
Fever†38 (67)
Days from symptom onset to exanthema1 (0–2)
Arthralgia33 (58)
Itching32 (56)
Headache38 (67)
Myalgia28 (49)
Retro-orbital pain23 (40)
Conjunctivitis22 (39)
Joint swelling13 (23)

*Median (interquartile range) or no. (%) case-patients.
†Measured in medical office (n = 30) or self-reported (n = 8).

*Median (interquartile range) or no. (%) case-patients.
†Measured in medical office (n = 30) or self-reported (n = 8). Our clinic-based study of 57 rRT-PCR–confirmed cases of Zika virus disease found rash to be the most common symptom for which patients sought care (98%); fever, generally low-grade, was reported or observed in 67%. Because our study design was retrospective in nature, wherein we reviewed records for selected patients in whom Zika was subsequently found to be laboratory-confirmed by using rRT-PCR, we may have introduced selection bias to our sample, limiting the generalizability and comparability of our results. For example, clinic staff may have seen patients with mild symptoms but decided not to test for the virus, leading to a bias toward testing patients with more severe rash. It is also possible, considering the retrospective nature of our data collection, that some data points were not accurately recorded and could not be validated. Despite these limitations, our data suggest the term “Zika fever” is not a helpful substitute term for Zika virus disease. Furthermore, referring to the illness caused by this virus as “Zika fever” () may be misleading and should probably be avoided until further more systematic studies clarify the frequency of fever as a symptom. Although patient sampling and laboratory testing methods are not directly comparable to our study, a 2015–2016 assessment in Puerto Rico detected Zika virus in 30 of 155 case-patients in whom Zika virus disease was suspected. In that study, laboratory-confirmed disease was defined as detection of Zika virus RNA by using rRT-PCR or IgM by using ELISA. Among the 30 confirmed cases, the most frequently reported signs and symptoms were rash (77%), myalgia (77%), arthralgia (73%), and fever (73%) (). The February 12, 2015, interim case definition published by the World Health Organization describes a suspected case-patient as a person with rash, fever, or both, in addition to 1 of 3 other listed symptoms (). Like the Puerto Rico report, our report supports the established World Health Organization case definition indicating that the presence of rash, fever, or both should be emphasized as primary characteristics of Zika virus disease.
  8 in total

1.  Zika virus. I. Isolations and serological specificity.

Authors:  G W A DICK; S F KITCHEN; A J HADDOW
Journal:  Trans R Soc Trop Med Hyg       Date:  1952-09       Impact factor: 2.184

2.  Local Transmission of Zika Virus--Puerto Rico, November 23, 2015-January 28, 2016.

Authors:  Dana L Thomas; Tyler M Sharp; Jomil Torres; Paige A Armstrong; Jorge Munoz-Jordan; Kyle R Ryff; Alma Martinez-Quiñones; José Arias-Berríos; Marrielle Mayshack; Glenn J Garayalde; Sonia Saavedra; Carlos A Luciano; Miguel Valencia-Prado; Steve Waterman; Brenda Rivera-García
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-02-19       Impact factor: 17.586

3.  Zika virus outbreak on Yap Island, Federated States of Micronesia.

Authors:  Mark R Duffy; Tai-Ho Chen; W Thane Hancock; Ann M Powers; Jacob L Kool; Robert S Lanciotti; Moses Pretrick; Maria Marfel; Stacey Holzbauer; Christine Dubray; Laurent Guillaumot; Anne Griggs; Martin Bel; Amy J Lambert; Janeen Laven; Olga Kosoy; Amanda Panella; Brad J Biggerstaff; Marc Fischer; Edward B Hayes
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

Review 4.  Zika fever.

Authors:  Pablo Martínez de Salazar; Anna Suy; Adrián Sánchez-Montalvá; Carlota Rodó; Fernando Salvador; Israel Molina
Journal:  Enferm Infecc Microbiol Clin       Date:  2016-03-15       Impact factor: 1.731

5.  First report of autochthonous transmission of Zika virus in Brazil.

Authors:  Camila Zanluca; Vanessa Campos Andrade de Melo; Ana Luiza Pamplona Mosimann; Glauco Igor Viana Dos Santos; Claudia Nunes Duarte Dos Santos; Kleber Luz
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-06-09       Impact factor: 2.743

6.  Zika Virus Outbreak, Bahia, Brazil.

Authors:  Gubio S Campos; Antonio C Bandeira; Silvia I Sardi
Journal:  Emerg Infect Dis       Date:  2015-10       Impact factor: 6.883

7.  Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007.

Authors:  Robert S Lanciotti; Olga L Kosoy; Janeen J Laven; Jason O Velez; Amy J Lambert; Alison J Johnson; Stephanie M Stanfield; Mark R Duffy
Journal:  Emerg Infect Dis       Date:  2008-08       Impact factor: 6.883

8.  Zika virus in Gabon (Central Africa)--2007: a new threat from Aedes albopictus?

Authors:  Gilda Grard; Mélanie Caron; Illich Manfred Mombo; Dieudonné Nkoghe; Statiana Mboui Ondo; Davy Jiolle; Didier Fontenille; Christophe Paupy; Eric Maurice Leroy
Journal:  PLoS Negl Trop Dis       Date:  2014-02-06
  8 in total
  33 in total

1.  A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques.

Authors:  So-Yon Lim; Christa E Osuna; Katharine Best; Ray Taylor; Elsa Chen; Gyeol Yoon; Jessica L Kublin; Dane Schalk; Nancy Schultz-Darken; Saverio Capuano; David Safronetz; Ma Luo; Steve MacLennan; Amanda Mathis; Yarlagadda S Babu; William P Sheridan; Alan S Perelson; James B Whitney
Journal:  Sci Transl Med       Date:  2020-06-10       Impact factor: 17.956

Review 2.  Animal Models of Zika Virus Infection, Pathogenesis, and Immunity.

Authors:  Thomas E Morrison; Michael S Diamond
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 3.  Key points on Zika infection for the intensivist.

Authors:  Fernando A Bozza; Beatriz Grinsztejn
Journal:  Intensive Care Med       Date:  2016-05-12       Impact factor: 17.440

Review 4.  Zika clinical updates: implications for pediatrics.

Authors:  Kristina Adachi; Karin Nielsen-Saines
Journal:  Curr Opin Pediatr       Date:  2018-02       Impact factor: 2.856

5.  Characterization of cis-Acting RNA Elements of Zika Virus by Using a Self-Splicing Ribozyme-Dependent Infectious Clone.

Authors:  Zhong-Yu Liu; Jiu-Yang Yu; Xing-Yao Huang; Hang Fan; Xiao-Feng Li; Yong-Qiang Deng; Xue Ji; Meng-Li Cheng; Qing Ye; Hui Zhao; Jian-Feng Han; Xiao-Ping An; Tao Jiang; Bo Zhang; Yi-Gang Tong; Cheng-Feng Qin
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

6.  Neural progenitor cell pyroptosis contributes to Zika virus-induced brain atrophy and represents a therapeutic target.

Authors:  Zhenjian He; Shu An; Jiahui Chen; Shuqing Zhang; Chahui Tan; Jianchen Yu; Hengming Ye; Yun Wu; Jie Yuan; Jueheng Wu; Xun Zhu; Mengfeng Li
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-09       Impact factor: 11.205

Review 7.  Emerging and re-emerging infectious diseases in Japan: epidemiology and infection prevention measures.

Authors:  Satoshi Kutsuna
Journal:  Glob Health Med       Date:  2019-12-31

8.  Zika Virus Infection in Tupaia belangeri Causes Dermatological Manifestations and Confers Protection against Secondary Infection.

Authors:  Na-Na Zhang; Li Zhang; Yong-Qiang Deng; Yue Feng; Feng Ma; Qi Wang; Qing Ye; Yuanyuan Han; Xiaomei Sun; Fu-Chun Zhang; Xiaopeng Qi; Guoqing Wang; Jiejie Dai; Xueshan Xia; Cheng-Feng Qin
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

9.  Zika viral dynamics and shedding in rhesus and cynomolgus macaques.

Authors:  Christa E Osuna; So-Yon Lim; Claire Deleage; Bryan D Griffin; Derek Stein; Lukas T Schroeder; Robert Were Omange; Katharine Best; Ma Luo; Peter T Hraber; Hanne Andersen-Elyard; Erwing Fabian Cardozo Ojeda; Scott Huang; Dana L Vanlandingham; Stephen Higgs; Alan S Perelson; Jacob D Estes; David Safronetz; Mark G Lewis; James B Whitney
Journal:  Nat Med       Date:  2016-10-03       Impact factor: 53.440

Review 10.  Emerging Role of Zika Virus in Adverse Fetal and Neonatal Outcomes.

Authors:  Alice Panchaud; Miloš Stojanov; Anne Ammerdorffer; Manon Vouga; David Baud
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.